Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial

@article{Dhainaut2003DrotrecoginA,
  title={Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial},
  author={Jean-François Dhainaut and P. -F. Laterre and Jonathan Marcus Janes and Gordon R. Bernard and Antonio Artigas and Jan Bakker and Hanno B Riess and Bruce R. Basson and Julien Charpentier and Barbara G. Utterback and J K Vincent},
  journal={Intensive Care Medicine},
  year={2003},
  volume={29},
  pages={894-903}
}
Objective. Based on the results of the PROWESS trial the European Agency for the Evaluation of Medicinal Products has recently approved drotrecogin alfa (activated) for treatment of adult patients with severe sepsis and multiple-organ failure. We report study's data on efficacy and safety in patients with multiple-organ dysfunction. Design and setting. Randomized, double-blind, placebo-controlled, multicenter trial in 164 medical centers. Patients. 1271 patients (75.2% of the intention-to… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 44 references

Similar Papers

Loading similar papers…